Trending...
- Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community
- LiteracyNation's 3rd Annual Indie Author Book Fair
- International Rights Groups Raise Alarm Over Freedom of Religion and Expression in South Korea
WEST CHESTER, Pa., Sept. 16, 2021 /PRNewswire/ -- VESTECK, Inc., an early-stage medical device company, is pleased to announce the additional close of funds totaling >$5.2M of Series A financing, which includes conversion of all existing convertible notes.
Philadelphia area investors BioAdvance (https://www.bioadvance.com/) and Angel Network (https://angelstarventures.com/) Kennett Square, PA lead these additional investments, joined by several other investors.
The Series A funds will support the manufacturing of products, pre-clinical testing and completion of in human procedures, prior to our clinical study for FDA clearance.
VESTECK has designed a platform technology comprised of 6 devices that integrate the delivery of nitinol sutures into a catheter, improving clinical outcomes for endovascular aortic aneurysm patients.
Dr. Rick Jones, BioAdvance Partner said, "BioAdvance is very excited to support the VESTECK "Suture-Tight" technology and team. We appreciate that VESTECK is answering a significant global unmet need for patients and physicians."
More on The PennZone
The "Suture-Tight" catheter delivers nitinol sutures more easily than current endovascular or surgical options, securing endovascular aortic repair grafts to the aorta at initial implant or in repair procedures.
Dr. David H. Deaton, Chief Medical Officer, says, "the Suture-Tight catheter makes the process faster, easier and safer for physicians and patients. Suture-Tight will become the standard of care in EVAR."
Vesteck expects to bring significant incremental revenue to an aortic repair market projected to be $4.5B by 2028.
VESTECK CEO Joe Rafferty stated, "We are absolutely honored that our $3.5M Series A round has been over subscribed to this extent, a further recognition of this significant opportunity."
About Vesteck Inc.:
VESTECK, Inc. (WWW.VESTECK.com) is an early-stage medical device company focused on bringing their proprietary technology to the aortic repair, structural heart and GI markets.
Their first product, the "Suture-Tight" nitinol suture delivery catheter will bring a novel technology to endovascular aortic repair market solving a significant global challenge for physicians and patients.
VESTECK was represented by Kevin M. Granahan of Fox Rothschild LLP
MEDIA CONTACTS:
BioAdvance VESTECK, Inc.
Dr. Frederick Jones Joe Rafferty
Partner CEO
(508) 314-5347 610-457-7324
SOURCE VESTECK, Inc.
Related Links
http://VESTECK.com
Philadelphia area investors BioAdvance (https://www.bioadvance.com/) and Angel Network (https://angelstarventures.com/) Kennett Square, PA lead these additional investments, joined by several other investors.
The Series A funds will support the manufacturing of products, pre-clinical testing and completion of in human procedures, prior to our clinical study for FDA clearance.
VESTECK has designed a platform technology comprised of 6 devices that integrate the delivery of nitinol sutures into a catheter, improving clinical outcomes for endovascular aortic aneurysm patients.
Dr. Rick Jones, BioAdvance Partner said, "BioAdvance is very excited to support the VESTECK "Suture-Tight" technology and team. We appreciate that VESTECK is answering a significant global unmet need for patients and physicians."
More on The PennZone
- Rebecca L. Francis, Founder of the Rebecca Francis Team, Named to Lehigh Valley Business' LVB 300
- Crossroads4Hope Marks 25 Years Ensuring No One Faces Cancer Alone At its Inspiring Hope Gala
- Imagen Golf & Top 100 Coach Daniel Guest Voted Best Golf Instruction Firm of the Year 2026
- Q1 2026 Arizona Technology Industry Impact Report Recaps Advanced Manufacturing Growth, High-Value Jobs and Workforce Investment
- Former Prosecutor Opens Stegall Law in Summerville
The "Suture-Tight" catheter delivers nitinol sutures more easily than current endovascular or surgical options, securing endovascular aortic repair grafts to the aorta at initial implant or in repair procedures.
Dr. David H. Deaton, Chief Medical Officer, says, "the Suture-Tight catheter makes the process faster, easier and safer for physicians and patients. Suture-Tight will become the standard of care in EVAR."
Vesteck expects to bring significant incremental revenue to an aortic repair market projected to be $4.5B by 2028.
VESTECK CEO Joe Rafferty stated, "We are absolutely honored that our $3.5M Series A round has been over subscribed to this extent, a further recognition of this significant opportunity."
About Vesteck Inc.:
VESTECK, Inc. (WWW.VESTECK.com) is an early-stage medical device company focused on bringing their proprietary technology to the aortic repair, structural heart and GI markets.
Their first product, the "Suture-Tight" nitinol suture delivery catheter will bring a novel technology to endovascular aortic repair market solving a significant global challenge for physicians and patients.
VESTECK was represented by Kevin M. Granahan of Fox Rothschild LLP
MEDIA CONTACTS:
BioAdvance VESTECK, Inc.
Dr. Frederick Jones Joe Rafferty
Partner CEO
(508) 314-5347 610-457-7324
SOURCE VESTECK, Inc.
Related Links
http://VESTECK.com
0 Comments
Latest on The PennZone
- Stop Bleeding Cash on Mediocre Talent. Build a Powerhouse Remote Team Instead
- Crownlight Strategies® Announces Federal Trademark Registration
- New Book Calls 'Sense of Belonging' the Missing Link in Student Success
- Igbozue Connecticut USA Celebrates 2026 Summer Family Picnic
- KT Medical Staffing Addresses the Questions Families Forget to Ask Before Bringing Private Nursing Care Home
- Private Autopsies Give Arizona Families Answers After Nursing Home and Care Facility Deaths
- Chuckie F. Mahoney Memorial Foundation Awards Nearly $40,000 in School Grants
- OPUS Global Data Solutions Launches Food Trader Plus, Bringing Operational Control and Deal-Level Profit Visibility to Food Brokers
- Phinge CEO DeMaio Unveils Speech to Congress: User Data Sovereignty vs Tech Surveillance Capitalism, Asserting Foundational 2021 App-Less Patents & IP
- Michael Maertens Hired as Century Fasteners Corp. – Chief Financial Officer
- LATO AI Software Innovations Expedite Inspections & Repair of Parking Lots for The Pavement Group
- Built to Last: Why BSI Is Among the Nation's Fastest-Growing Companies, and One of Its Best Places to Work
- Bent Danholm's The Architecture of Demand Reaches No. 2 in Amazon Real Estate Sales
- Contracting Resources Group Named to Inc. 5000 for the Ninth Time
- Nola Blue Records to Release John Németh's Illinois Central in March 2027
- ImagineX Named to 2026 Inc. 5000 List of America's Fastest-Growing Private Companies
- ASSIST Software Becomes One of the First European Companies Certified to ISO/IEC 42001
- The World's No.1 Superstar® Enters the Occult with New Track and Cinematic Visual "Under Your Spell"
- PricZone Launches Online Shopping Platform Offering Electronics, Gaming, and More
- Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community